Given the pivotal role of PARP1 in ovarian cancer, particularly in BRCA1/2 mutant ovarian cancer (where these cancer cells exhibit homologous recombination repair deficiencies and are more reliant on the PARP1-mediated single-strand repair pathway), PARP1 inhibitors such as olaparib and niraparib have emerged. Here, BRCA1 is linked to cancer.